Status:
UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis
Lead Sponsor:
German University in Cairo
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is considered a condition that arises when the body's response to an infection injures i...
Detailed Description
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is considered a life-threatening condition that arises when the body's response to an in...
Eligibility Criteria
Inclusion
- Age more than 18 years old.
- A diagnosis of sepsis according to the latest Sepsis-3 definition
- Estimated GFR \>45 ml/min
Exclusion
- • Immunosuppressed or end stage cancer.
- Septic Shock.
- Pregnancy and breast feeding.
- Patients on metformin, Sodium glucose cotransporters or Gliptins.
- End stage hepatic disease.
- Contraindications to metformin (chronic respiratory failure, chronic cardiac failure, chronic kidney or liver disease, myocardial infarction within the last month).
- Patients with hypersensitivity to metformin.
Key Trial Info
Start Date :
September 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 10 2024
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT05979038
Start Date
September 10 2023
End Date
July 10 2024
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al Demerdash University Hospital
Cairo, Egypt